Successful combined therapy with Glucantime™ and pentoxifylline for the nasal mucosal lesion recently developed in a leishmaniasis patient having untreated cutaneous lesion for seven decades.
Case report
Meglumine antimoniate
Mucocutaneous leishmaniasis
Pentoxifylline
Treatment
Journal
Parasitology international
ISSN: 1873-0329
Titre abrégé: Parasitol Int
Pays: Netherlands
ID NLM: 9708549
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
31
03
2020
revised:
12
07
2021
accepted:
13
07
2021
pubmed:
20
7
2021
medline:
29
10
2021
entrez:
19
7
2021
Statut:
ppublish
Résumé
Leishmaniasis is a worldwide problem and has been neglected in a wide range of fields, from diagnosis to treatment. This report describes a case of mucosal leishmaniasis, which may developped after seven decades of an inadequately treated cutaneous lesion. A female patient, 79 years old, from the non-endemic area for leishmaniasis in northern Paraná, presenting mucosal lesion in the nose and throat, reported an "angry ulcer" treated inappropriately as a child when she lived in an endemic region of the state of São Paulo. Indirect immunofluorescence and direct parasite screening were positive. Polymerase chain reaction detected a parasite belonging to the subgenus Leishmania (Viannia) sp. Due to patients limitations, such as low weight and advanced age, the therapeutic model adopted was the combined small doses of Glucantime™ to pentoxifylline, which ensured treatment success.
Identifiants
pubmed: 34280531
pii: S1383-5769(21)00140-9
doi: 10.1016/j.parint.2021.102422
pii:
doi:
Substances chimiques
Trypanocidal Agents
0
Meglumine Antimoniate
75G4TW236W
Pentoxifylline
SD6QCT3TSU
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102422Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.